ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 126 filers reported holding ATEA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,357,651 | -39.1% | 6,452,550 | -24.1% | 0.00% | -33.3% |
| Q2 2023 | $31,779,924 | -59.0% | 8,497,306 | -63.3% | 0.00% | -25.0% |
| Q1 2023 | $77,541,640 | +37.3% | 23,146,758 | +97.2% | 0.00% | -33.3% |
| Q4 2022 | $56,456,937 | -20.6% | 11,737,409 | -6.0% | 0.01% | -14.3% |
| Q3 2022 | $71,061,000 | -20.2% | 12,488,746 | -0.4% | 0.01% | -22.2% |
| Q2 2022 | $89,030,000 | -2.0% | 12,539,475 | -0.3% | 0.01% | +28.6% |
| Q1 2022 | $90,826,000 | -18.5% | 12,579,791 | +0.9% | 0.01% | -12.5% |
| Q4 2021 | $111,441,000 | -74.4% | 12,465,409 | +0.4% | 0.01% | -77.1% |
| Q3 2021 | $435,324,000 | +63.3% | 12,416,533 | +0.0% | 0.04% | +66.7% |
| Q2 2021 | $266,579,000 | -59.9% | 12,410,530 | +15.4% | 0.02% | -63.2% |
| Q1 2021 | $664,357,000 | +146.6% | 10,758,795 | +66.9% | 0.06% | +137.5% |
| Q4 2020 | $269,384,000 | – | 6,447,692 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | $17,648,000 | 2.07% |
| EcoR1 Capital, LLC | 6,340,639 | $45,019,000 | 1.55% |
| CM Management, LLC | 200,000 | $1,420,000 | 1.51% |
| K2 PRINCIPAL FUND, L.P. | 1,606,059 | $11,403,000 | 1.26% |
| Cormorant Asset Management, LP | 1,547,181 | $10,985,000 | 0.83% |
| Privium Fund Management (UK) Ltd | 61,284 | $435,000 | 0.49% |
| Atom Investors LP | 30,911 | $219,000 | 0.10% |
| FEDERATED HERMES, INC. | 3,588,131 | $25,476,000 | 0.07% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 347,612 | $2,468,000 | 0.06% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,799,507 | $12,777,000 | 0.04% |